Yu Chaowen, Tang Wenbo, Lu Ran, Tao Yuan, Ren Tiancai, Gao Yong
Department of Vascular Surgery, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Ann Palliat Med. 2021 Feb;10(2):2123-2133. doi: 10.21037/apm-21-49.
Mesenchymal stem cells (MSCs) have shown great potential in the treatment of cardiovascular diseases, with fat being a more accessible source of MSCs. This study investigated the effect of human adipose-derived mesenchymal stem cells (hMSCs-Ad) exosomes on T lymphocytes and its role in atherosclerosis (AS).
The exosomes were preliminarily isolated hMSCs-Ad and co-cultured with human H9 T lymphocytes. The effects of hMSCs-Ad exosomes on the proliferation and apoptosis of H9 were examined by performing functional experiments. The serum lipid level and inflammatory factor level in tail vein of mice were measured by biochemical analyzer and enzyme linked immunosorbent assay (ELISA) respectively.
The hMSCs-Ad-derived exosomes up-regulate the expression of micro (mi)R-125b-1-3p in H9 and AS arterial tissues. miR-125b-1-3p shared a targeted binding site with B-cell chronic lymphocytic leukemia (CLL)/lymphoma 11B gene (BCL11B). miR-125b-1-3p negatively regulated the expression of BCL11B in H9, and that knocking down BCL11B in H9 promoted its apoptosis. Injection of hMSCs-Ad-derived exosomes via the tail vein effectively reduced blood lipid and inflammatory factors, and that relieved the symptoms of AS in AS model mice.
miR-125b-1-3p was expressed in hMSCs-Ad exosomes and can promote T lymphocyte apoptosis and alleviate AS by down-regulating BCL11B expression. It provides potential molecular targets for the clinical treatment of AS.
间充质干细胞(MSCs)在心血管疾病治疗中显示出巨大潜力,脂肪是更易获取的MSCs来源。本研究调查了人脂肪来源的间充质干细胞(hMSCs-Ad)外泌体对T淋巴细胞的影响及其在动脉粥样硬化(AS)中的作用。
从hMSCs-Ad中初步分离出外泌体,并与人H9 T淋巴细胞共培养。通过功能实验检测hMSCs-Ad外泌体对H9细胞增殖和凋亡的影响。分别用生化分析仪和酶联免疫吸附测定(ELISA)法检测小鼠尾静脉中的血脂水平和炎症因子水平。
hMSCs-Ad来源的外泌体上调H9细胞和AS动脉组织中微小(mi)R-125b-1-3p的表达。miR-125b-1-3p与B细胞慢性淋巴细胞白血病(CLL)/淋巴瘤11B基因(BCL11B)有靶向结合位点。miR-125b-1-3p在H9细胞中负向调节BCL11B的表达,敲低H9细胞中的BCL11B可促进其凋亡。通过尾静脉注射hMSCs-Ad来源的外泌体可有效降低血脂和炎症因子水平,并缓解AS模型小鼠的AS症状。
miR-125b-1-3p在hMSCs-Ad外泌体中表达,可通过下调BCL11B表达促进T淋巴细胞凋亡并减轻AS。它为AS的临床治疗提供了潜在的分子靶点。